Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28911308 | 0.87 | MAPT (0.40) | MAPTPKMKDM4ENPC1CASP3 | |
| SCHEMBL3019240 | 0.85 | KDM4E (0.46) | MAPTPKMKDM4ENPC1CASP3 | |
| SCHEMBL11502797 | 0.84 | L3MBTL1 (0.40) | MAPTPKMKDM4ENPC1CASP3 | |
| SCHEMBL25202606 | 0.82 | MAPT (0.38) | MAPTPKMKDM4ENPC1CASP3 | |
| SCHEMBL8779802 | 0.82 | KDM4E (0.40) | MAPTPKMKDM4ENPC1CASP3 | |
| SCHEMBL10591189 | 0.80 | DAO (0.44) | PKMKMT2ATSHRMEN1TDP1 | |
| SCHEMBL11014523 | 0.78 | MAPT (0.43) | MAPTPKMKDM4ENPC1NPSR1 | |
| SCHEMBL9529269 | 0.77 | TSHR (0.45) | MAPTKDM4ENPC1CASP3RAB9A | |
| SCHEMBL9729920 | 0.76 | CYP3A4 (0.40) | MAPTKDM4ENPC1RAB9AKMT2A | |
| SCHEMBL4360547 | 0.76 | MAPT (0.58) | MAPTKDM4ENPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693498-B | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116693498-A | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-1699372-A | Process for synthesizing lornoxicam intermediate against inflammation and pain | UNIV JIANGSU POLYTECHNIC (CN) | 2005-11-23 | — | — | CN | claimed |
| CN-119409709-A | Lornoxicillin preparation method of kang | 黑龙江乌苏里江制药有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| CN-116693498-B | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-116693498-B | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-116693498-B | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116693498-A | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116693498-A | Method for synthesizing 5-chloro-3- (chlorosulfonyl) -2-thiophenecarboxylic acid methyl ester by utilizing continuous flow reaction | 湖北广济医药科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| EP-2188272-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV Remynd (BE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
| CN-1699372-A | Process for synthesizing lornoxicam intermediate against inflammation and pain | UNIV JIANGSU POLYTECHNIC (CN) | 2005-11-23 | — | — | CN | disclosed |
| CN-1028101-C | Process for preparation of 5-chloro-3-chlorosulphony 1-2-thiophenecarboxylic acid esters | CL PHARMA (AT) | 1995-04-05 | — | — | CN | disclosed |
| US-5138072-A | Process for the preparation of 5-chloro-3-chlorosulphonyl-2-thiophenecarboxylic acid esters | HAFSLUND NYCOMED PHARMA AKTIENGESELLSCHAFT (AT) | 1992-08-11 | — | — | US | disclosed |
| CN-1037511-A | The preparation method of 5-chloro-3-chlorosulfonyl-2-Thiophene Carboxylic Acid ester | CL PHARMA (AT) | 1989-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAPT 9/4885PKM 1944/4885KDM4E 4164/4885 |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | MAPT 18/4885PKM 1047/4885KDM4E 4398/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | MAPT 107/4885PKM 1668/4885KDM4E 3151/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAPT 9/4885PKM 1944/4885KDM4E 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.